Cargando…
Time to inclusion in clinical guidance documents for non-oncological orphan drugs and biologics with expedited FDA designations: a retrospective survival analysis
OBJECTIVES: Drug and biological products that treat rare, serious or life-threatening conditions can receive US Food and Drug Administration (FDA) orphan designation and expedited programme designations (accelerated approval, breakthrough therapy, fast track or priority review) meant to incentivise...
Autores principales: | Rodriguez, Ryan, Brunner, Rachel, Spencer, Samantha, Qato, Dima M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719201/ http://dx.doi.org/10.1136/bmjopen-2021-057744 |
Ejemplares similares
-
Effectiveness, safety and costs of orphan drugs: an evidence-based review
por: Onakpoya, Igho J, et al.
Publicado: (2015) -
Use of antimicrobial dressings in England and the association with published clinical guidance: interrupted time series analysis
por: Hussey, Louise, et al.
Publicado: (2019) -
Barriers and facilitators to orthopaedic surgeons’ uptake of decision aids for total knee arthroplasty: a qualitative study
por: Bunzli, Samantha, et al.
Publicado: (2017) -
Protocol for assessing the determinants of preoperative test-ordering behaviour for low-risk surgical procedures using a theoretically driven, qualitative design
por: Pike, Andrea, et al.
Publicado: (2020) -
Shared decision-making for people living with dementia in extended care settings: a systematic review
por: Daly, Rachel Louise, et al.
Publicado: (2018)